Hoe 140 a new potent and long acting bradykinin-antagonist: in vivo studies
about
Kallistatin is a potent new vasodilatorInduction of selective blood-tumor barrier permeability and macromolecular transport by a biostable kinin B1 receptor agonist in a glioma rat modelIcatibant: HOE 140, JE 049, JE049Bradyzide, a potent non-peptide B(2) bradykinin receptor antagonist with long-lasting oral activity in animal models of inflammatory hyperalgesiaEvidence for activation of the tissue kallikrein-kinin system in nociceptive transmission and inflammatory responses of mice using a specific enzyme inhibitorIn various tumour cell lines the peptide bradykinin B(2) receptor antagonist, Hoe 140 (Icatibant), may act as mitogenic agonistChanges in blood glucose and plasma insulin levels induced by bradykinin in anaesthetized ratsThe nonpeptide B2 receptor antagonist FR173657: inhibition of effects of bradykinin related to its role in nociceptionCharacterization of the capsaicin-sensitive component of cyclophosphamide-induced inflammation in the rat urinary bladderThe nonpeptide WIN 64338 is a bradykinin B2 receptor antagonistMediation by prostaglandins of the nitric oxide-induced neurogenic vasodilatation in rat skinThe role of endogenous bradykinin in blood pressure homeostasis in spontaneously hypertensive ratsExpression and function of bradykinin B1 and B2 receptors in normal and inflamed rat urinary bladder urotheliumCollaboration for rare disease drug discovery researchNegatively Charged Silver Nanoparticles Cause Retinal Vascular Permeability by Activating Plasma Contact System and Disrupting Adherens JunctionSynthesis and analysis of potent, more lipophilic derivatives of the bradykinin B2 receptor antagonist peptide Hoe 140.Bradykinin does not mediate cutaneous active vasodilation during heat stress in humans.A specific B2-bradykinin receptor antagonist HOE 140 abolishes the antihypertrophic effect of ramiprilEffect of inflammatory mediators on ATP release of human urothelial RT4 cells.Prologue: kinins and related systems. New life for old discoveries.Identification of receptor ligands and receptor subtypes using antagonists in a capillary electrophoresis single-cell biosensor separation system.Inhibition of bradykinin receptor B1 protects mice from focal brain injury by reducing blood-brain barrier leakage and inflammationMetalloendopeptidases EC 3.4.24.15/16 regulate bradykinin activity in the cerebral microvasculature.The hypothalamus and hypertension.The involvement of bradykinin B1 and B2 receptor mechanisms in cytokine-induced mechanical hyperalgesia in the rat.Involvement of B2 receptors in the bradykinin-induced relaxation of guinea-pig isolated trachea.Role of bradykinin in the hyperaemia following acid challenge of the rat gastric mucosaAttenuation of the antiarrhythmic effects of ischaemic preconditioning by blockade of bradykinin B2 receptorsThe identification of an orally active, nonpeptide bradykinin B2 receptor antagonist, FR173657Effects of FR173657, a non-peptide B2 antagonist, on kinin-induced hypotension, visceral and peripheral oedema formation and bronchoconstrictionEffects of the non-peptide B2 antagonist FR173657 on kinin-induced smooth muscle contraction and relaxation, vasoconstriction and prostaglandin release.Effects of trout bradykinin on the motility of the trout stomach and intestine: evidence for a receptor distinct from mammalian B1 and B2 subtypesEffects of a nonpeptide bradykinin B2 receptor antagonist, FR167344, on different in vivo animal models of inflammationEffect of chronic bradykinin B2 receptor blockade on blood pressure of conscious Dahl salt-resistant ratsRamipril-induced delayed myocardial protection against free radical injury involves bradykinin B2 receptor-NO pathway and protein synthesisReduction of sodium deoxycholic acid-induced scratching behaviour by bradykinin B2 receptor antagonists.Suppressive effect of distinct bradykinin B2 receptor antagonist on allergen-evoked exudation and leukocyte infiltration in sensitized rats.Effect of a kinin B2 receptor antagonist on LPS- and cytokine-induced neutrophil migration in rats.Mechanism of kinin release during experimental acute pancreatitis in rats: evidence for pro- as well as anti-inflammatory roles of oedema formationBradykinin antagonist counteracts the acute effect of both angiotensin-converting enzyme inhibition and of angiotensin receptor blockade on the lower limit of autoregulation of cerebral blood flow.
P2860
Q24561603-47D45C83-09B1-431A-96DD-3D02C47E3394Q27302402-49F9EAD4-ACED-49EC-98C5-DE9B67AD27EDQ28295050-269BDD79-9F78-4D15-9678-9B44DD78E207Q28343952-81923426-EE4C-420C-9D20-1369EFF376A9Q28344415-79B2BB7F-672F-4C21-A0C6-D0DDF54C96F6Q28345556-877DCC12-87EF-40DB-BE4C-64BE5C9C1997Q28363779-D4166E32-5129-43B9-9935-CDF1B4413485Q28368657-73CB8043-9FAC-48C7-9B57-CD8DEEFAE98EQ28369304-29E175EC-1642-404A-B657-83ABBDF65995Q28369725-2CF15C63-B277-4EC1-8447-904FC83F4F74Q28378779-FCCD8187-81E5-4E6A-AF8A-6E9AC24DF2A5Q28379232-9ACB7B63-C0AA-4809-A09C-41A997946228Q28581310-ED14A026-6401-463B-AE7C-0052B1665F9BQ28650560-95FB3D1B-5F62-466C-B110-F14E84D50A6EQ29248661-F1EFCCD0-2A8B-450C-9F82-0425C9FF40ECQ30833851-79F11841-FD85-4059-A832-6A4FA2899BA3Q31109527-682CA65D-6C29-4CE6-A100-3BA9AE507DDCQ33189033-54C93046-3118-4DBA-A8C3-7D524C3695CBQ33563019-64AA0A4C-D05F-4C0F-AD34-41859C0EE691Q33965979-0BD118D6-FDAA-4310-8FA2-3F66D6EB9372Q34014790-47E8FF37-7FE0-4D9E-9B92-843C30051D1AQ34171305-E87A8416-359E-40A0-A766-C8EA47EBC92EQ34177185-82E55F53-F2E4-4D2B-BAF7-B7447BBBA2B8Q34388100-5637F413-6394-4719-AB0C-85F54DD17500Q34792254-CCA51E29-C734-40DD-ABC7-A907C9B4A486Q34792752-1566BED5-E124-44E3-9C96-DC6853E76F7BQ34793427-AE0B5225-1D30-42B3-80C5-D85ACD61EF68Q34793682-D555D245-B657-4927-9F86-73A48CB4BCC8Q35025764-F8DCD30A-CEB3-406B-9DA6-A98BBCEAE717Q35025808-C69AEF8F-DDF7-4770-9C30-2D3F33274BD4Q35026239-84C09059-2DC1-49CC-9C2A-FDE916EE035BQ35026257-B80A6CA2-DE10-4511-A823-8BF8060777B4Q35026961-4EF2518D-D2E1-4B03-A923-70D990EA8C84Q35027507-28C7E38D-D51D-4D3A-983D-5A068CDB94BCQ35028061-3AA607D3-293D-46F0-8FC2-A5F790A60F4AQ35028380-61A8AA64-7D3F-41D3-80B8-714376A8670AQ35028820-5F133699-3EBC-469A-BC6E-475393D9A8C1Q35045282-AA5DE564-A419-4835-9A45-B392B1E6637DQ35045310-2024ECDF-F76C-4119-AFFB-6088ECD48D87Q35064653-87D0A8E3-F8E9-48BF-9507-55DCD1D089F6
P2860
Hoe 140 a new potent and long acting bradykinin-antagonist: in vivo studies
description
1991 nî lūn-bûn
@nan
1991 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
1991 թվականի մարտին հրատարակված գիտական հոդված
@hy
1991年の論文
@ja
1991年論文
@yue
1991年論文
@zh-hant
1991年論文
@zh-hk
1991年論文
@zh-mo
1991年論文
@zh-tw
1991年论文
@wuu
name
Hoe 140 a new potent and long acting bradykinin-antagonist: in vivo studies
@ast
Hoe 140 a new potent and long acting bradykinin-antagonist: in vivo studies
@en
type
label
Hoe 140 a new potent and long acting bradykinin-antagonist: in vivo studies
@ast
Hoe 140 a new potent and long acting bradykinin-antagonist: in vivo studies
@en
prefLabel
Hoe 140 a new potent and long acting bradykinin-antagonist: in vivo studies
@ast
Hoe 140 a new potent and long acting bradykinin-antagonist: in vivo studies
@en
P2093
P2860
P3181
P1476
Hoe 140 a new potent and long acting bradykinin-antagonist: in vivo studies
@en
P2093
Alpermann HG
Anagnostopoulos H
Breipohl G
Schölkens BA
P2860
P304
P3181
P356
10.1111/J.1476-5381.1991.TB12249.X
P407
P577
1991-03-01T00:00:00Z